A randomized, double blind, placebo and active controlled, dose escalation study to evaluate the safety, tolerability and potential efficacy of a 12-week treatment with YM543 in subjects with type 2 diabetes mellitus.

Trial Profile

A randomized, double blind, placebo and active controlled, dose escalation study to evaluate the safety, tolerability and potential efficacy of a 12-week treatment with YM543 in subjects with type 2 diabetes mellitus.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs YM 543 (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Oct 2008 Status changed from recruiting to completed.
    • 15 Oct 2008 Actual patient number (97) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top